**CASE REPORT**

**Transient severe hypotension with once-weekly subcutaneous injection of teriparatide in osteoporotic patient: a case report and insight for the drug interaction between hypotensive agents and teripаратide**

Tetsuya Enishi1, Hirokazu Uemura2, Shinsuke Katoh1, Masanori Inatsugi3, Sho Minato4, Kei Inatsugi4, Mikiko Inatsugi4, Nori Sato1, and Koichi Siryo4

1Departments of Rehabilitation Medicine, The Tokushima University Hospital, Tokushima, Japan, 2Department of Preventive Medicine, Institute of Health Biosciences, University of Tokushima Graduate School, Tokushima, Japan, 3Departments of Orthopedics and Rehabilitation Medicine, The Inatsugi rehabilitation clinic, Tokushima, Japan, 4Departments of Orthopedics, The Tokushima University Hospital, Tokushima, Japan

Abstract: Teriparatide, a recombinant form of parathyroid hormone, were well recognized as a useful option for the treatment of the osteoporosis. Although some side effects of teriparatide include headache, nausea, dizziness, and limb pain were reported. Here we present a 80-year-old woman of transient asymptomatic hypotension with once-weekly subcutaneous injection of teriparatide for the treatment of osteoporosis with hypertension disease as acute-phase reactions. Systolic blood pressure decreased in both 30 min and 60 min after injection compared with before injection. Heart rate increased with passage of time. Statistically significant were observed among before, 30 min, 60 min after injection of teriparatide. Slight nausea was seen as subjective symptoms with the first and second injection after 30 min. This case indicates careful attention, at least 1 hr, was recommended with weekly subcutaneous injections of teriparatide in the treatment for osteoporotic patient with hypertension decreases. This is a first report, to the best of our knowledge, to demonstrate the transient asymptomatic hypotension after once-weekly injection of teriparatide with hypertension disease. Transient hypotension occurred after injection of teriparatide during the treatment period and was asymptomatic except for the first 2 injections. J. Med. Invest. 62: 93-96, February, 2015

**Keywords**: osteoporosis, teriparatide, blood pressure, hypotension, side effect

**INTRODUCTION:**

Teriparatide, a recombinant form of parathyroid hormone, were well recognized as a useful option for the treatment of the osteoporosis (1-3). Intermittent injection of teriparatide activates osteoblasts and results in increase in bone mineral density (1, 3). It has been demonstrated to effectively reduce vertebral and non-vertebral fractures, and back pain in postmenopausal osteoporotic patients (3-6). Some side effects of teriparatide include headache, nausea, dizziness, and limb pain were reported as “common” to “very common” by the European Medicines Agency (3, 7, 8). Although reports of decreased blood pressure after injection of teriparatide were present, there is no detailed case report about the severe reduction in blood pressure of each injection and suggesting drug interaction between hypotensive agents and teriparatide. This potential drug interaction and its clinical consequences have not been discussed.

Here we present a 80-year-old woman of transient asymptomatic hypotension as acute-phase reactions with once-weekly subcutaneous injection of teriparatide for the treatment of osteoporosis with hypertension disease. Systolic, diastolic blood pressure and heart rate after injection were studied. To the best of our knowledge, this is the first report about the severe reduction in blood pressure of each injection of once-weekly teriparatide and suggesting drug interaction with hypotensive agents.

**CASE PRESENTATION:**

A 80-year-old woman with hypertension disease had a chronic low back pain due to spondylolisthesis at L1/5 and old lumbar compression fractures at L2, L3, and L4 (Figure 1). She consulted our clinic to relief of her low back pain. She was 54 kg and 144 cm; body mass index was 26.0 kg/m². Body metabolic markers, P1NP (1-34), teriparatide acetate, TERIBONETM, were evaluated before and after treatment (Table 1). She had not been receiving anti-osteoporotic medical therapy, although the patient had hypertension disease treated with hypotensive agents, valsartan (80 mg/day), hydrochlorothiazide (12.5 mg/day), atenolol (25 mg/day), and amiodipine besilate (6.95 mg/day), once a day in the morning. The physical examination was normal without neurological signs, except for an apparent slight thoraco-lumbar kyphosis. All laboratory findings were within normal limits. She has no history of autonomic dysfunction and transient hypotensive reaction.

Once-weekly subcutaneous injection of teriparatide (1-34), teriparatide acetate, TERIBONE™, 56.5 mg, Asahi Kasei Pharma, Tokyo, Japan), injected at 14 O’clock, was applied to the patient for 24 weeks. As a safety management, systolic, diastolic blood pressure and heart rate were measured before, 30 min. after, and 60 min. after every subcutaneous injection of teriparatide. Blood pressure was measured using automatic devices (AC 05P, SUZUKEN CO., LTD. Aichi, Japan.) in sitting position with the
arms supported precisely at the right atrium level. The subjective symptoms were also interviewed at every blood pressure measurement.

Transient asymptomatic hypotension was observed each time of subcutaneous injection of teriparatide. Slight nausea was seen as subjective symptoms with the first and second injection after 30 min. Systolic blood pressure, diastolic blood pressure, and heart rate were shown in Figure 2. Systolic blood pressure decreased in both 30 min and 60 min after injection compared with before injection. Systolic blood pressure was still low after 60 min, but slightly recovered. Diastolic pressure decreased after 30 min injection, but recovered in 60 min. There were no significant difference between before and 60 min after injection. Heart rate slightly increased with passage of time. Statistically significant in heart rate were observed among before, 30 min, 60 min after injection of teriparatide. This slight tachycardia was intended to compensate for the decrease in blood pressure. However, these increase were small and considered to be less clinical significance. The changes in bone metabolic markers and bone mineral density in this case were also small and clinically not significant (Table 1). These results were consistent with previous report (9). At one-year follow-up, low back pain decreased and no other side effect of the treatment was observed.

DISCUSSION

According to the formally prescribing information (10), the maximum decrease of systolic and diastolic blood pressure during their clinical pharmacological test was 4.6 mmHg and 8.8 mmHg, respectively. In this case, the maximum decrease of systolic and diastolic blood pressure was 66 mmHg and 32 mmHg, respectively. These

Table 1. The change in bone mineral density and bone metabolic markers.

<table>
<thead>
<tr>
<th></th>
<th>Before treatment</th>
<th>After treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BMD at spine</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(T-score)</td>
<td>0.982 g/cm² (0.97)</td>
<td>1.002 g/cm² (0.99)</td>
</tr>
<tr>
<td><strong>BMD at femoral</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>neck (T-score)</td>
<td>0.487 g/cm² (0.62)</td>
<td>0.485 g/cm² (0.62)</td>
</tr>
<tr>
<td><strong>P1NP</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>46.6 μg/l</td>
<td>56.3 μg/l</td>
<td></td>
</tr>
<tr>
<td><strong>TRAcP-5b</strong></td>
<td>448 mU/dl</td>
<td>402 mU/dl</td>
</tr>
</tbody>
</table>

Bone metabolic markers were evaluated one week before the first injection of teriparatide and after the last injection of teriparatide. Bone mineral density (BMD).

Figure 1. Anteroposterior (A) and lateral (B) radiographs. Spondylolisthesis (natural fusion) at L4/5 and old lumbar compression fractures at L2, L3, and L4 were observed.

Figure 2. Line graphs demonstrating systolic blood pressure (A), diastolic blood pressure (B), and heart rate (C). Statistical analyses were performed using SPSS v. 21.0. Values of p < 0.05 were considered significantly different. The effects of teriparatide were analyzed using a Friedman test. The homogeneity of variances was analyzed using the Shapiro-Wilk normality test. *, statistically significant difference.
strikingly decreases were observed after 30 min injection compared with the maximum decrease in blood pressure prescribed in the formal information (8). This is the first report describing such a severe transient hypotension after once-weekly injection of teriparatide.

The mechanism of hypotension after injection of teriparatide was generally believed due to the vasodilating action through the vascular smooth muscle relaxant activity, accompanied by pulse increase (11, 12). Hypotension has multiple possible causes, and hypotensive agents such as Ca2+ antagonist reduce vascular smooth muscle tone with increase of vessel diameter and decrease of the blood pressure (13). Transient hypotension reaction in this case may have reflected the response to multiple hypotensive agents rather than the consequence of a drug interaction between hypotensive agents and teriparatide (14). However, hypotensive reaction had never been observed without injection of teriparatide during follow up period. This case indicates the necessity considering the drug interaction between hypotensive agents and teriparatide, although there is no such description in the formal information and no report suggesting the drug interaction between hypotensive agents and teriparatide.

This case also showed that most hypotensive side effects did not cause the subjective symptom. Although systolic and diastolic blood pressure decreased after each injection of teriparatide, transient hypotension was usually asymptomatic except for the first 2 injections. The decrease of systolic blood pressure after first injection and second injection was 17 mmHg and 28 mmHg, respectively. As far in this patient, these decreases were the average changes for her. Given the results from this case, there is a possibility that asymptomatic decrease in blood pressure might occur in acute phase after injection of teriparatide.

CONCLUSION

Here we show a severe transient asymptomatic hypotension with once-weekly subcutaneous injection of teriparatide for the treatment of osteoporosis with hypertension disease as acute-phase reactions. This is a first report showing transient severe hypotension after once-weekly injection of teriparatide in acute phase, and suggesting the drug interaction between hypotensive agents and teriparatide. This case indicates careful attention, at least 1 hr, was recommended with injections of teriparatide in the treatment for osteoporotic patient with hypertension decreases. There is a possibility that transient hypotension might occur without symptoms in acute phase after injection of teriparatide.

CONSENT

Written informed consent was obtained from the patient for publication of this Case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

COMPETING INTERESTS

The authors declare that they have no competing interests.

ACKNOWLEDGEMENTS

The authors thanks to Dr. Yuichiro Goda, MD from the Department of Orthopedics of the Tokushima University Hospital, Tokushima, for kind advises.

REFERENCES

